Columbia Psychiatry Pathways

The Depression Algorithm

Veröffentlicht von: avoMD

Beschreibung

Designed by expert psychiatrists from Columbia University and delivered via cutting-edge, interactive technology from avoMD, this evidence-based app provides a practical and easy-to-use treatment algorithm for major depression.
This app incorporates Columbia’s Accelerated Sequential Antidepressant Protocol (ASAP) © 2021 The Trustees of Columbia University in the City of New York. Complete with calculators to assess depression severity (PHQ-9 and Columbia Depression Scale), bipolar screening, and suicide risk assessment, this app puts all the information you need to treat depression at your fingertips. Also included are clinical pearls such as how to titrate antidepressants and manage common side effects.
A revamp of the STAR*D Trial published in 2006, ASAP recommends rapid titrations and follow-up with a focus on the 7 best-tolerated generic antidepressants, providing a quicker and easier way to treat depression.
Columbia Psychiatry Pathways is intended for use in outpatient settings by psychiatrists, primary care physicians, nurse practitioners, physician assistants, medical students, residents, and trainees as they treat patients with depression.
FEATURES:
- Designed by experts from Columbia University's Department of Psychiatry and delivered via avoMD's next-gen decision support technology
- Regularly updated to reflect the latest research, with external links to the evidence
- Provides clinical pearls for depression treatment, including a walkthrough of titration recommendations, management of common side effects, and more
- Covers the 7 essential meds you need to know to effectively treat outpatient depression
- Includes recommendations on managing DSM-5 depression and screening for bipolar disorder and suicide risk
- Measure symptom severity using built-in calculators for Patient Health Questionnaire-9 item (PHQ-9) and the Columbia Depression Scale
- Intended for outpatient settings to aid psychiatrists, primary care physicians, nurse practitioners, physician assistants, and trainees make real-time psychopharmacologic decisions
- Functions as a teaching and learning tool for program directors, residents, med
students, and other trainees
Ranked #3 in NIH funding and in the top 5 psychiatry hospitals in the country by US News, the Department of Psychiatry at Columbia University has been a preeminent academic psychiatry department for over 100 years. Columbia Psychiatry faculty have led the development of the Diagnostic and Statistical Manual of Mental Disorders (DSM) and served as leaders in the field including the current National Institutes of Mental Health Director. The inventors of this clinical algorithm are J. John Mann, MD, co-director of Columbia’s Center for the Prevention and Treatment of depression and a leading researcher in the field of mood disorders, and Ravi N. Shah, MD, MBA, a pioneer in digital mental health and the department’s Chief Innovation Officer.
avoMD transforms clinical guidelines, pathways, and algorithms into interactive, next-gen decision support apps, made available as standalone mobile and web apps and via EHR integrations. Leading academic medical centers, urgent cares, and trainee programs are using avoMD to digitize their clinical content and put them in the hands of their providers or distribute them externally. In randomized control trials and usability studies, the software has been shown to save providers time while improving clinical accuracy. Current investors and supporters include Columbia University’s Lang Entrepreneurship Center, Mount Sinai Innovation Partners’ Elementa Labs, StartUp Health, and 500 Startups. The team is led by physicians and informaticians from Columbia, Harvard, and Yale.
Subscriptions ($19.99 / year) automatically renew unless auto-renew is turned off. Cancellations at least 24 hours prior to subscription renewal will not be charged. You can manage your subscription and auto-renewal from your Apple ID account settings after purchase.
Ausblenden Mehr anzeigen...

In-App-Käufe

Individual Plan
€20.49

Screenshots

Columbia Psychiatry Pathways Häufige Fragen

  • Ist Columbia Psychiatry Pathways kostenlos?

    Ja, Columbia Psychiatry Pathways ist kostenlos herunterzuladen, enthält jedoch In-App-Käufe oder Abonnements.

  • Ist Columbia Psychiatry Pathways seriös?

    Nicht genügend Bewertungen, um eine zuverlässige Einschätzung vorzunehmen. Die App benötigt mehr Nutzerfeedback.

    Danke für die Stimme

  • Wie viel kostet Columbia Psychiatry Pathways?

    Columbia Psychiatry Pathways bietet mehrere In-App-Käufe/Abonnements, der durchschnittliche In-App-Preis beträgt €20.49.

  • Wie hoch ist der Umsatz von Columbia Psychiatry Pathways?

    Um geschätzte Einnahmen der Columbia Psychiatry Pathways-App und weitere AppStore-Einblicke zu erhalten, können Sie sich bei der AppTail Mobile Analytics Platform anmelden.

Benutzerbewertung
Die App ist in Österreich noch nicht bewertet.
Bewertungsverlauf

Columbia Psychiatry Pathways Bewertungen

Extremely helpful and educational!

scMD90 on

Vereinigte Staaten

A user-friendly app that makes treating depression in the primary care setting easier, and makes mental health treatment more accessible to patients. The app can be tailored to each physician’s comfort level. The evidence-based algorithm also serves as a valuable educational tool.

Amazing clinical tool

NPMD90 on

Vereinigte Staaten

This app is an amazing tool in helping physicians manage depression on their own, to their own comfort level. Their treatment pathways, backed by evidence in the app, are easy to use and make a complex topic manageable. Would recommend this to any internist or specialist who is looking for a helpful adjunct to their practice!

Great app. Easier to navigate than up to date.

Kye Ye on

Vereinigte Staaten

With a few clicks I can get recommendations for anti depressant initiation and titration. Would be great for pcps to use.

Amazing UI

DrPajama on

Vereinigte Staaten

omg this is crazy

Game changing tool!

s10023 on

Vereinigte Staaten

Super intuitive UI that walks you through each step- an amazing tool!

Very helpful for primary care

DR UMP on

Vereinigte Staaten

This app is easy to use and provides the level of detail I need as I need it. It helps make managing complex patients easy. I recommend this to any doctor as we all ultimately treat patients with depression.

Great app for depression

Ya!r on

Vereinigte Staaten

Many of my patients are on SSRIs, this is incredibly helpful! Thank you

Easy, Informative, Best App for Depression

dr_wise on

Vereinigte Staaten

Have been looking for this for years to help me treat patients. This is a game changer. So glad it exists!!! Please add pathways for anxiety, sleep disorders, substance abuse disorders

Store-Rankings

Ranking-Verlauf
App-Ranking-Verlauf noch nicht verfügbar
Kategorien-Rankings
App ist noch nicht gerankt

Columbia Psychiatry Pathways Konkurrenten

Name
Waco Guide- Psychopharmacology
Clinical Decision Support
NEI Prescribe
Maudsley Prescribing Guideline
Psychiatry Prescribing
NEI Learn
PsychNotes: Clinical Pkt Guide
DSM-5 disorders and treatments
SMI Adviser
Psychiatric Disorders
from @Point of Care™
CURRENT Dx Tx Psychiatry
LANGE Series Concise format
APA eBooks
Case Files Psychiatry, 6e
Sixty high-yield cases - Lange

Columbia Psychiatry Pathways Installationen

Letzte 30 Tage

Columbia Psychiatry Pathways Umsatz

Letzte 30 Tage

Columbia Psychiatry Pathways Einnahmen und Downloads

Gewinnen Sie wertvolle Einblicke in die Leistung von Columbia Psychiatry Pathways mit unserer Analytik.
Melden Sie sich jetzt an, um Zugriff auf Downloads, Einnahmen und mehr zu erhalten.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.